References
- Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer [Internet]. 2015 Mar 1 [cited 2018 May 22];136(5):E359–86. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25220842
- Gridelli C, Rossi A, Carbone DP, et al. Non-small-cell lung cancer. Nat Rev Dis Prim [Internet]. 2015 May 21 [cited 2019 Feb 8];1:15009. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27188576
- Li T, Kung H-J, Mack PC, et al., Genotyping and genomic profiling of non–small-cell lung cancer: implications for current and future therapies. J Clin Oncol [Internet]. 2013 Mar 10 [cited 2019 Jan 3];31(8):1039–1049. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23401433
- Herbst RS, Morgensztern D, Boshoff C, The biology and management of non-small cell lung cancer. Nat [Internet]. 2018 Jan 24 [cited 2019 Feb 8];553(7689):446. Available from: https://www.nature.com/articles/nature25183
- Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature [Internet]. 2013 Aug 14 [cited 2019 Feb 8];500(7463):415–421. Available from: http://www.nature.com/articles/nature12477
- Khalil DN, Smith EL, Brentjens RJ, et al., The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol [Internet]. 2016 May 15 [cited 2019 Feb 8];13(5):273–290. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26977780
- Wei SC, Levine JH, Cogdill AP, et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell [Internet]. 2017 Sep 7 [cited 2019 Feb 8];170(6):1120–1133.e17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28803728
- Wu Y, Shi H, Jiang M, et al. The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety. Int J Cancer [Internet]. 2017 Dec 15 [cited 2019 Feb 8];141(12):2562–2570. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28833119
- Wood DE, Chair V, Aisner DL, et al. NCCN Guidelines Version 3.2019. Non-Small Cell Lung Cancer [Internet]]. 2019 [cited 2019 Feb 8]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
- Yang JC-H, Wu Y-L, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol [Internet] 2015 Feb [cited 2019 Feb 8];16(2):141–151. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25589191
- Dariavach P, Mattéi M-G, Golstein P, et al. Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. Eur J Immunol [Internet]. 1988 Dec [cited 2019 Feb 8];18(12):1901–1905. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3220103
- Ling V, Wu PW, Finnerty HF, et al., Complete sequence determination of the mouse and human CTLA4 gene loci: cross-species DNA sequence similarity beyond exon borders. Genomics [Internet]. 1999 Sep 15 [cited 2019 Feb 8];60(3):341–355. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10493833
- Krummel MF, Allison JP, CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med [Internet]. 1995 Aug 1 [cited 2019 Feb 8];182(2):459–465. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7543139
- Leach DR, Krummel MF, Allison JP, Enhancement of antitumor immunity by CTLA-4 blockade. Science [Internet]. 1996 Mar 22 [cited 2018 Oct 1];271(5256):1734–1736. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8596936
- Yang YF, Zou JP, Mu J, et al. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res [Internet]. 1997 Sep 15 [cited 2019 Feb 8];57(18):4036–4041. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9307290
- Shrikant P, Khoruts A, Mescher MF. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity [Internet]. 1999 Oct [cited 2019 Feb 8];11(4):483–493. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10549630
- Hoos A, Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov [Internet]. 2016 Apr 11 [cited 2019 Feb 8];15(4):235–247. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26965203
- Alegre M-L, Frauwirth KA, Thompson CB, T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol [Internet]. 2001 Dec 1 [cited 2019 Feb 8];1(3):220–228. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11905831
- Walker LSK, Sansom DM. Confusing signals: recent progress in CTLA-4 biology. Trends Immunol [Internet]. 2015 Feb [cited 2019 Feb 8];36(2):63–70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25582039
- Egen JG, Kuhns MS, Allison JP, CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol [Internet]. 2002 Jul 1 [cited 2019 Feb 8];3(7):611–618. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12087419
- Rozali EN, Hato SV, Robinson BW, et al. Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol [ [Internet]. 2012 Apr 29 [cited 2019 Feb 8];2012:1–8. Available from: http://www.hindawi.com/journals/jir/2012/656340/
- Bardhan K, Anagnostou T, Boussiotis VA. The PD1: PD-L1/2Pathway from discovery to clinical implementation. Front Immunol [Internet]. 2016 [cited 2019 Feb 8];7:550. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28018338
- He M, Chai Y, Qi J, et al. Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies. Oncotarget [Internet]. 2017 Sep 15 [cited 2019 Feb 8];8(40):67129–67139. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28978021
- Ramagopal UA, Liu W, Garrett-Thomson SC, et al. Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab. Proc Natl Acad Sci [Internet]. 2017 May 23 [cited 2019 Feb 8];114(21):E4223–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28484017
- Feng Y, Masson E, Dai D, et al. Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma. Br J Clin Pharmacol [Internet]. 2014 Jul [cited 2019 Feb 8];78(1):106–117. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24433434
- Sheng J, Srivastava S, Sanghavi K, et al. Clinical pharmacology considerations for the development of immune checkpoint inhibitors. J Clin Pharmacol [Internet]. 2017 Oct [cited 2019 Feb 8];57:S26–42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28921644
- Postow MA, Chasalow SD, Yuan J, et al. Pharmacodynamic effect of ipilimumab on absolute lymphocyte count (ALC) and association with overall survival in patients with advanced melanoma. ASCO; Journal of Clinical Oncology. 2013;31(15_suppl):9052–9052.
- Horinouchi H, Yamamoto N, Fujiwara Y, et al. Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer. Invest New Drugs [Internet]. 2015 Aug 1 [cited 2019 Feb 8];33(4):881–889. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25924991
- Antonia SJ, Gettinger SN, Chow LQM, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results. J Clin Oncol [Internet]. 2014 May 20 [cited 2019 Feb 8];32(15_suppl):8023. Available from: http://ascopubs.org/doi/10.1200/jco.2014.32.15_suppl.8023
- Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2016 Dec 10;18(1):31–41. 2017.
- Gubens MA, Sequist LV, Stevenson J, et al. Phase I/II study of pembrolizumab (pembro) plus ipilimumab (ipi) as second-line therapy for NSCLC: KEYNOTE-021 cohorts D and H. J Clin Oncol [Internet]. 2016 May 20 [cited 2019 Feb 8];34(15_suppl):9027. Available from: http://ascopubs.org/doi/10.1200/JCO.2016.34.15_suppl.9027
- Tang C, Welsh JW, de Groot P, et al. Ipilimumab with stereotactic ablative radiation therapy: phase I results and immunologic correlates from peripheral T cells. Clin Cancer Res [Internet]. 2017 Mar 15 [cited 2019 Feb 8];23(6):1388–1396. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27649551
- Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol [Internet]. 2012 Jun 10 [cited 2019 Feb 8];30(17):2046–2054. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22547592
- Iafolla MAJ, Juergens RA. Update on programmed death-1 and programmed death-ligand 1 inhibition in the treatment of advanced or metastatic non-small cell lung cancer. Front Oncol. 2017;7:14.
- Ramalingam SS, Hellmann MD, Awad MM, et al. Abstract CT078: tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568. Cancer Res [Internet]. 2018 Jul 1 [cited 2019 Feb 8];78(13 Supplement):CT078–CT078. Available from: http://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.AM2018-CT078
- Hellmann MD, Ciuleanu T-E, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med [Internet]. 2018 May 31 [cited 2019 Feb 8];378(22):2093–2104. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1801946
- Weber JS, Kähler KC, Hauschild A, Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol [Internet]. 2012 Jul 20 [cited 2019 Feb 8];30(21):2691–2697. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22614989
- Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res [Internet]. 2015 Oct [cited 2019 Feb 8];4(5):560–575. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26629425
- Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol [Internet]. 2017 Jan [cited 2019 Feb 8];18(1):31–41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27932067
- Williams TJ, Benavides DR, Patrice K-A, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol [Internet]. 2016 Aug 1 [cited 2019 Feb 8];73(8):928. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27271951
- Ito M, Fujiwara S, Fujimoto D, et al. Rituximab for nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patient. Ann Oncol [Internet]. 2017 Sep 1 [cited 2019 Feb 8];28(9):2318–2319. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28911080
- Zhu J, Wu J, Li G, et al. Meta-analysis of randomized controlled trials for the incidence and risk of fatal adverse events in cancer patients treated with ipilimumab. Expert Opin Drug Saf [Internet]. 2017 Apr 3 [cited 2019 Feb 8];16(4):423–428. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28276859
- Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med [Internet]. 2016 Nov 3 [cited 2019 Feb 8];375(18):1749–1755. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1609214
- Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med [Internet]. 2014 Dec 4 [cited 2019 Feb 8];371(23):2189–2199. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1406498
- Van Allen EM, Miao D, Schilling B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Sci (80- ) [Internet]. 2015 Oct 9 [cited 2019 Feb 8];350(6257):207–211. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26359337
- Ock C-Y, Hwang J-E, Keam B, et al. Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. Nat Commun [Internet]. 2017 Dec 19 [cited 2019 Feb 8];8(1):1050. Available from: http://www.nature.com/articles/s41467-017-01018-0
- Patel SJ, Sanjana NE, Kishton RJ, et al. Identification of essential genes for cancer immunotherapy. Nature [Internet]. 2017 Aug 7 [cited 2019 Feb 8];548(7669):537–542. Available from: http://www.nature.com/doifinder/10.1038/nature23477
- Jacquelot N, Roberti MP, Enot DP, et al. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat Commun [Internet]. 2017 Dec 19 [cited 2019 Feb 8];8(1):592. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28928380
- Delyon J, Mateus C, Lefeuvre D, et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol [Internet]. 2013 Jun [cited 2019 Feb 8];24(6):1697–1703. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23439861
- Ferrucci PF, Ascierto PA, Pigozzo J, et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol [Internet]. 2016 Apr [cited 2019 Feb 8];27(4):732–738. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26802161
- Martens A, Wistuba-Hamprecht K, Yuan J, et al. Increases in absolute lymphocytes and circulating CD4+ and CD8+ T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab. Clin Cancer Res [Internet]. 2016 Oct 1 [cited 2019 Feb 8];22(19):4848–4858. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27169993
- Martens A, Wistuba-Hamprecht K, Foppen MG, et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res [Internet]. 2016 Jun 15 [cited 2019 Feb 8];22(12):2908–2918. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26787752
- Wilgenhof S, Du Four S, Vandenbroucke F, et al. Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma. J Immunother [Internet]. 2013 Apr [cited 2019 Feb 8];36(3):215–222. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23502769
- Krajsová I, Arenberger P, Lakomý R, et al. Long-term survival with ipilimumab: experience from a national expanded access program for patients with melanoma. Anticancer Res [Internet]. 2015 Nov [cited 2019 Feb 8];35(11):6303–6310. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26504067
- Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res [Internet]. 2007 Nov 15 [cited 2019 Feb 8];13(22):6681–6688. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17982122